We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
Read MoreHide Full Article
Sanofi (SNY - Free Report) and partner Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
The IL-6R antibody has been approved for the treatment of adult patients in combination with methotrexate (MTX) with moderate-to-severely active RA, who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs) such as MTX.
So far this year, Sanofi’s shares are up 22.8%, better than a 15% increase for the Zacks classified Large-Cap Pharma industry.
Kevzara was approved in the U.S. in May and in Canada in February this year for the same indication.
We remind investors that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted a positive opinion recommending marketing approval of Kevzara in the EU in April this year.
The marketing approval in the EU was based on results from seven phase III trials in the global SARIL-RA clinical development program conducted in more than 3,300 adults with moderate-to-severely active RA who had an inadequate response to previous treatment regimens. Kevzara demonstrated statistically significant, clinically-meaningful improvements in combination with conventional DMARDs, including MTX in two pivotal phase III studies.
While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.’s (ABBV - Free Report) Humira and Pfizer, Inc.’s (PFE - Free Report) Xeljanz among others. Moreover, the patient population is huge with many patients spending years on different treatments without achieving their treatment goals. With RA affecting about 2.9 million people in Europe, Kevzara represents a new treatment option for patients.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Image: Bigstock
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
Sanofi (SNY - Free Report) and partner Regeneron Pharmaceuticals, Inc. (REGN - Free Report) announced that the European Commission has granted marketing approval to its rheumatoid arthritis (RA) drug Kevzara.
The IL-6R antibody has been approved for the treatment of adult patients in combination with methotrexate (MTX) with moderate-to-severely active RA, who have had an inadequate response or intolerance to one or more biologic or non-biologic disease-modifying anti-rheumatic drugs (DMARDs) such as MTX.
So far this year, Sanofi’s shares are up 22.8%, better than a 15% increase for the Zacks classified Large-Cap Pharma industry.
Kevzara was approved in the U.S. in May and in Canada in February this year for the same indication.
We remind investors that the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted a positive opinion recommending marketing approval of Kevzara in the EU in April this year.
The marketing approval in the EU was based on results from seven phase III trials in the global SARIL-RA clinical development program conducted in more than 3,300 adults with moderate-to-severely active RA who had an inadequate response to previous treatment regimens. Kevzara demonstrated statistically significant, clinically-meaningful improvements in combination with conventional DMARDs, including MTX in two pivotal phase III studies.
While Kevzara has blockbuster potential, the RA market is highly crowded given the presence of treatments like AbbVie, Inc.’s (ABBV - Free Report) Humira and Pfizer, Inc.’s (PFE - Free Report) Xeljanz among others. Moreover, the patient population is huge with many patients spending years on different treatments without achieving their treatment goals. With RA affecting about 2.9 million people in Europe, Kevzara represents a new treatment option for patients.
Sanofi currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These are sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks ""Strong Sells"" absolutely free >>